Condition: Systemic Lupus Erythematosus (SLE) · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
This investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.
This description comes directly from the study's public registry record.
Xiaojun Tang · 18021397168 · xjtang09@163.com
Always discuss trial participation with your own doctor first.
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06946485